# A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

> **NCT00651664** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 59 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** alisertib

## Key facts

- **NCT ID:** NCT00651664
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-22
- **Primary completion:** 2010-09-01
- **Final completion:** 2011-04-05
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651664, "A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00651664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*